title: MTX clearance is more important for intermediate-risk ALL.
authors.forename: W E
authors.initials: WE
authors.lastname: Evans
authors.forename: M J
authors.initials: MJ
authors.lastname: Schell
authors.forename: C H
authors.initials: CH
authors.lastname: Pui
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D006801:Humans; D008727:Methotrexate / Q000493:pharmacokinetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000378:metabolism*; D012307:Risk Factors
chemical_list: D008727:Methotrexate